Table 3.

Accuracy measures of genomic studies for the systematic review.^a

Study, year	Model basisb	Predictor	Patients, n	Total sample (PCa+, PCa-)c	Crossvald/ split/none	TP,e n	FN,f n	FP,g n	TN,h n	Seni (lower-upper)	Spej (lower-upper)
Donovan, 2015 [62]	PB	Urine	195	195 (89, 106)	None	80	9	84	22	0.899 (0.817-0.947)	0.208 (0.141-0.295)
Roberts, 2015 [16]	PB	Semen	66	66 (12, 54)	Crossval	11	1	32	20	0.917 (0.587-0.988)	0.385 (0.263-0.522)
Zhang, 2015 [63]	PB	Serum	580	580 (180, 400)	320 (120, 200)	84	36	5	195	0.7 (0.612-0.775)	0.975 (0.941-0.99)
Mengual, 2016 [64]	PB	Urine	224	224 (15, 73)	Crossval	116	35	12	61	0.768 (0.694-0.829)	0.836 (0.732-0.904)
Salido-Guadarrama, 2016 [15]	PB	Urine	143	143 (73, 70)	None	60	13	13	57	0.822 (0.717-0.894)	0.814 (0.706-0.889)
Dereziński, 2017 [17]	PB	Serum	89	89 (49, 40)	34 (19, 15)	13	6	0	15	0.675 (0.449-0.841)	0.969 (0.65-0.998)
Dereziński, 2017a [17]	PB	Urine	89	89 (49, 40)	34 (19,15)	17	2	4	11	0.895 (0.663-0.974)	0.733 (0.467-0.896)
Kirby, 2017 [60]	LB	Tissue	101	398 (286, 112)	262 (213, 49)	180	33	4	45	0.845 (0.79-0.888)	0.918 (0.802-0.969)
Barceló, 2018 [65]	PB	Semen	42	42 (34, 18)	None	22	2	5	13	0.917 (0.721-0.979)	0.722 (0.481-0.879)
Amante, 2019 [66]	PB	Urine	91	91 (43, 48)	Crossval	40	3	5	43	0.93 (0.805-0.977)	0.896 (0.773-0.956)
Brikun, 2019 [67]	PB	Urine	94	94 (42, 52)	29 (13, 16)	12	1	5	11	0.923 (0.609-0.989)	0.687 (0.433-0.864)
Gao, 2019 [69]	PB	Urine	183	183 (108, 75)	77 (55, 22)	48	7	5	17	0.873 (0.756-0.938)	0.773 (0.556-0.902)
Patel, 2019 [61]	LB	Tissue	699	795 (699, 96)	242 (212, 30)	199	13	2	28	0.939 (0.897-0.964)	0.933 (0.769-0.983)
Santotoribio, 2019 [68]	PB	Serum	232	232 (32, 200)	None	30	2	58	142	0.937 (0.782-0.984)	0.71 (0.643-0.769)

^aAll studies employed regression-based models.

^bLB: lesion-based model; PB: patient-based model.

^cPCa: prostate cancer.

^dCrossval: cross-validation techniques.

^eTP: true-positive.

^fFN: false-negative.

^gFP: false-positive.

^hTN: true-negative.

ⁱSen: sensitivity.

^jSpe: specificity.